Equity Overview
Price & Market Data
Price: $30.90
Daily Change: -$0.20 / 0.65%
Daily Range: $30.21 - $31.20
Market Cap: $3,585,649,920
Daily Volume: 1,785,992
Performance Metrics
1 Week: 1.77%
1 Month: -7.04%
3 Months: -17.82%
6 Months: 20.79%
1 Year: -1.90%
YTD: -11.80%
Company Details
Employees: 53
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.